🇺🇸 FDA
Patent

US 9315811

Methods for modulating kallikrein (KLKB1) expression

granted A61KA61K31/7125A61P

Quick answer

US patent 9315811 (Methods for modulating kallikrein (KLKB1) expression) held by Ionis Pharmaceuticals, Inc. expires Mon Apr 14 2036 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
Ionis Pharmaceuticals, Inc.
Grant date
Tue Apr 19 2016 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Apr 14 2036 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
22
CPC classes
A61K, A61K31/7125, A61P, A61P7/10